Thus, the success of Byetta catalyzed a competitive race to create improved GLP-1 drugs
Providers should weigh discontinuation decisions carefully in these populations and discuss restart plans proactively if stopping is unavoidable
Chung, B ., Choi, S., Moon, I., Park, C., Kim, Y.-H
Using GLP-1 therapy and insulin safely together Safety depends largely on dose adjustments, monitoring and injecting at the right place to ensure consistent absorption
2b), which restricts the conformational flexibility of arbutin in this binding mode, thereby limiting opportunities for additional interactions
Lean mass loss can occur at any GLP-1 dose without resistance training and adequate protein intake